Generic Name and Formulations:
Brompheniramine maleate 2mg, pseudoephedrine HCl 30mg, dextromethorphan HBr 10mg; per 5mL; liq; contains alcohol 0.95% v/v; butterscotch flavor.
Indications for BROMFED-DM:
Cough and nasal congestion.
10mL every 4 hrs.
<2yrs: individualize. 2–6yrs: 2.5mL. 6–12yrs: 5mL. Both every 4 hrs. Max 6 doses/24 hours.
Asthma. Lower respiratory disorders. Neonates. Premature infants. Severe hypertension or cardiovascular disease. Within 14 days of MAOIs. Nursing mothers.
Diabetes. History of bronchial asthma. Glaucoma. GI or GU obstruction. Hypertension. Cardiovascular disease. Thyroid disease. Pregnancy (Cat.C).
See Contraindications. Hypertensive crisis with MAOIs. Potentiates alcohol, other CNS depressants. β-blockers may increase pressor effects of sympathomimetics. Antagonizes antihypertensives.
Antihistamine + antitussive + sympathomimetic.
Sedation, dizziness, anticholinergic effects, thickening of bronchial secretions; excitability in children.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|